Study backs anti-TNFs for rheumatology patients with COVID-19

Monotherapy gave the best outcomes in an analysis of data from three registries
Reuters Health
Coronavirus particles

Pooled data from three international COVID-19 registries support the use of TNF inhibitor monotherapy in patients with rheumatoid arthritis and other immune-mediated inflammatory diseases.

But, compared to TNF inhibitor monotherapy, some other therapies — including methotrexate monotherapy, Janus kinase (JAK) inhibitors or azathioprine/6-mercaptopurine — worsen the odds of severe COVID-19 in such patients, the investigators report.